Stay updated with breaking news from Johan Dalsgaard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The AIR trial is a single arm, multicenter phase 2 study in patients with idiopathic pulmonary fibrosis (IPF)Interim data have shown stabilization of the disease and an increase in lung capacity
First healthy volunteer dosed with C106 in a phase 1 trialC106 is the first new angiotensin II type 2 receptor agonist (ATRAG) from Vicore's VP03 programTopline data expected Q1 2023GOTHENBURG
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...
First clinical study with a digital therapy (DTx) in patients with IPF to address the psychological symptom burden in this diseaseFirst patient enrolled in US pilot phase leading up to the US
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company, today announces the first patient enrolled in the pilot...